Cargando…

Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors

PURPOSE: Before anaplastic lymphoma kinase (ALK) inhibitors, treatment options for ALK-positive inflammatory myofibroblastic tumors (AP-IMTs) were unsatisfactory. We retrospectively analyzed the outcome of patients with AP-IMT treated with crizotinib to document response, toxicity, survival, and fea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trahair, Toby, Gifford, Andrew J., Fordham, Ashleigh, Mayoh, Chelsea, Fadia, Mitali, Lukeis, Robyn, Wood, Andrew C., Valvi, Santosh, Walker, Roderick D., Blackburn, James, Heyer, Erin E., Mercer, Tim R., Barbaric, Draga, Marshall, Glenn M., MacKenzie, Karen L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	Original Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446396/ https://www.ncbi.nlm.nih.gov/pubmed/32914017 http://dx.doi.org/10.1200/PO.18.00297

Ejemplares similares

CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma
por: Fordham, Ashleigh M., et al.
Publicado: (2020)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
por: Nagumo, Yoshiyuki, et al.
Publicado: (2018)

ALK(G1269A) mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Michels, Sebastian Y. F., et al.
Publicado: (2017)

Efficiency of Crizotinib on an ALK-Positive Inflammatory Myofibroblastic Tumor of the Central Nervous System: A Case Report
por: Chennouf, Anas, et al.
Publicado: (2017)

ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report
por: Xu, Xiaojing, et al.
Publicado: (2019)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
por: Mansfield, A. S., et al.
Publicado: (2016)

Crizotinib combined with bronchoscopic interventional treatment in ALK-positive inflammatory myofibroblastic tumor of left main stem bronchus: a case report
por: Zhang, Peng, et al.
Publicado: (2023)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy
por: Kamili, Alvin, et al.
Publicado: (2020)

Inflammatory Myofibroblastic Tumor: A Rare Presentation and an Effective Treatment with Crizotinib
por: Khalil, Sumaira, et al.
Publicado: (2020)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Boulos, Joelle C., et al.
Publicado: (2021)

Epithelioid Inflammatory Myofibroblastic Sarcoma With Poor Response to Crizotinib: A Case Report
por: Aminimoghaddam, Soheila, et al.
Publicado: (2023)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
por: Zhang, Xiangming, et al.
Publicado: (2023)

ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
por: Wilson, Christabel, et al.
Publicado: (2017)

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
por: Badran, Ahmed, et al.
Publicado: (2023)

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report
por: Wu, Xuan, et al.
Publicado: (2020)

PB2372: PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB
por: Shi, Wenyu
Publicado: (2023)

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787
por: Parker, Aulma R, et al.
Publicado: (2015)

Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen
por: Zhang, Sen, et al.
Publicado: (2011)

Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer
por: Yan, Hong Hua, et al.
Publicado: (2014)

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
por: Lin, Liping, et al.
Publicado: (2018)

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
por: Ye, Mingxiang, et al.
Publicado: (2016)

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy
por: Wu, Jinchun, et al.
Publicado: (2021)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022)

Transplant-Related Mortality Following Allogeneic Hematopoeitic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia: 25-Year Retrospective Review
por: Mateos, Marion K, et al.
Publicado: (2013)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia
por: Mateos, Marion K., et al.
Publicado: (2021)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK
por: Uchihara, Yuki, et al.
Publicado: (2017)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC
por: Weber, Daniel, et al.
Publicado: (2021)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mi68e9qmf45227u97ampgpurfa